Impact of and interplay between proton arc therapy and range uncertainties in proton therapy for head-and-neck cancer

被引:2
作者
Tattenberg, Sebastian [1 ,2 ,3 ]
Liu, Peilin [4 ]
Mulhem, Anthony [4 ,5 ]
Cong, Xiaoda [4 ]
Thome, Christopher [1 ,2 ]
Ding, Xuanfeng [4 ]
机构
[1] Laurentian Univ, Sudbury, ON P3E 2C6, Canada
[2] Northern Ontario Sch Med Univ, Sudbury, ON P3E 2C6, Canada
[3] TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
[4] William Beaumont Univ Hosp, Dept Radiat Oncol, Corewell Hlth, 3601 W 13 Mile Rd, Royal Oak, MI USA
[5] Michigan State Univ, Dept Human Biol, Nat Sci Bldg, 288 Farm Ln, E Lansing, MI 48824 USA
关键词
proton therapy; proton arc therapy; IMPT; PAT; SPArc; range uncertainty; VERIFICATION; OPTIMIZATION; DELIVERY; TISSUE; IMPT;
D O I
10.1088/1361-6560/ad2718
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Objective. Proton therapy reduces the integral dose to the patient compared to conventional photon treatments. However, in vivo proton range uncertainties remain a considerable hurdle. Range uncertainty reduction benefits depend on clinical practices. During intensity-modulated proton therapy (IMPT), the target is irradiated from only a few directions, but proton arc therapy (PAT), for which the target is irradiated from dozens of angles, may see clinical implementation by the time considerable range uncertainty reductions are achieved. It is therefore crucial to determine the impact of PAT on range uncertainty reduction benefits. Approach. For twenty head-and-neck cancer patients, four different treatment plans were created: an IMPT and a PAT treatment plan assuming current clinical range uncertainties of 3.5% (IMPT3.5% and PAT(3.5%)), and an IMPT and a PAT treatment plan assuming that range uncertainties can be reduced to 1% (IMPT1% and PAT(1%)). Plans were evaluated with respect to target coverage and organ-at-risk doses as well as normal tissue complication probabilities (NTCPs) for parotid glands (endpoint: parotid gland flow <25%) and larynx (endpoint: larynx edema). Main results. Implementation of PAT (IMPT3.5%-PAT(3.5%)) reduced mean NTCPs in the nominal and worst-case scenario by 3.2 percentage points (pp) and 4.2 pp, respectively. Reducing range uncertainties from 3.5% to 1% during use of IMPT (IMPT3.5%-IMPT1%) reduced evaluated NTCPs by 0.9 pp and 2.0 pp. Benefits of range uncertainty reductions subsequently to PAT implementation (PAT(3.5%)-PAT(1%)) were 0.2 pp and 1.0 pp, with considerably higher benefits in bilateral compared to unilateral cases. Significance. The mean clinical benefit of implementing PAT was more than twice as high as the benefit of a 3.5%-1% range uncertainty reduction. Range uncertainty reductions are expected to remain beneficial even after PAT implementation, especially in cases with target positions allowing for full leveraging of the higher number of gantry angles during PAT.
引用
收藏
页数:10
相关论文
共 36 条
[1]  
[Anonymous], PARTICLE THERAPY FAC
[2]   The potential of dual-energy CT to reduce proton beam range uncertainties [J].
Bar, Esther ;
Lalonde, Arthur ;
Royle, Gary ;
Lu, Hsiao-Ming ;
Bouchard, Hugo .
MEDICAL PHYSICS, 2017, 44 (06) :2332-2344
[3]   First-In-Human Validation of CT-Based Proton Range Prediction Using Prompt Gamma Imaging in Prostate Cancer Treatments [J].
Berthold, Jonathan ;
Khamfongkhruea, Chirasak ;
Petzoldt, Johannes ;
Thiele, Julia ;
Hoelscher, Tobias ;
Wohlfahrt, Patrick ;
Peters, Nils ;
Jost, Angelina ;
Hofmann, Christian ;
Janssens, Guillaume ;
Smeets, Julien ;
Richter, Christian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (04) :1033-1043
[4]  
Breedveld S, 2017, DATA BRIEF, V12, P143, DOI 10.1016/j.dib.2017.03.037
[5]   FITTING OF NORMAL TISSUE TOLERANCE DATA TO AN ANALYTIC-FUNCTION [J].
BURMAN, C ;
KUTCHER, GJ ;
EMAMI, B ;
GOITEIN, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01) :123-135
[6]   Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy [J].
Chang, Sheng ;
Liu, Gang ;
Zhao, Lewei ;
Dilworth, Joshua T. ;
Zheng, Weili ;
Jawad, Saada ;
Yan, Di ;
Chen, Peter ;
Stevens, Craig ;
Kabolizadeh, Peyman ;
Li, Xiaoqiang ;
Ding, Xuanfeng .
RADIATION ONCOLOGY, 2020, 15 (01)
[7]   Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients [J].
de Jong, Bas A. ;
Battinelli, Cecilia ;
Free, Jeffrey ;
Wagenaar, Dirk ;
Engwall, Erik ;
Janssens, Guillaume ;
Langendijk, Johannes A. ;
Korevaar, Erik W. ;
Both, Stefan .
MEDICAL PHYSICS, 2023, 50 (03) :1305-1317
[8]   PAROTID GLAND FUNCTION AFTER RADIOTHERAPY: THE COMBINED MICHIGAN AND UTRECHT EXPERIENCE [J].
Dijkema, Tim ;
Raaijmakers, Cornelis P. J. ;
Ten Haken, Randall K. ;
Roesink, Judith M. ;
Braam, Petra M. ;
Houweling, Anette C. ;
Moerland, Marinus A. ;
Eisbruch, Avraham ;
Terhaard, Chris H. J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (02) :449-453
[9]   Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy [J].
Ding, Xuanfeng ;
Li, Xiaoqiang ;
Zhang, J. Michele ;
Kabolizadeh, Peyman ;
Stevens, Craig ;
Yan, Di .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (05) :1107-1116
[10]   Online proton therapy monitoring: clinical test of a Silicon-photodetector-based in-beam PET [J].
Ferrero, Veronica ;
Fiorina, Elisa ;
Morrocchi, Matteo ;
Pennazio, Francesco ;
Baroni, Guido ;
Battistoni, Giuseppe ;
Belcari, Nicola ;
Camarlinghi, Niccolo ;
Ciocca, Mario ;
Del Guerra, Alberto ;
Donetti, Marco ;
Giordanengo, Simona ;
Giraudo, Giuseppe ;
Patera, Vincenzo ;
Peroni, Cristiana ;
Rivetti, Angelo ;
Rolo, Manuel Dionisio da Rocha ;
Rossi, Sandro ;
Rosso, Valeria ;
Sportelli, Giancarlo ;
Tampellini, Sara ;
Valvo, Francesca ;
Wheadon, Richard ;
Cerello, Piergiorgio ;
Bisogni, Maria Giuseppina .
SCIENTIFIC REPORTS, 2018, 8